So-Young Reports Unaudited Second Quarter 2024 Financial Results

Rhea-AI Summary

So-Young International Inc. (Nasdaq: SY) reported its Q2 2024 financial results. Total revenues were RMB407.4 million (US$56.1 million), slightly down 1.1% year-over-year but exceeding guidance. The company achieved net income of RMB18.9 million (US$2.6 million), compared to a net loss in Q2 2023. Non-GAAP net income increased to RMB22.2 million (US$3.1 million).

Key highlights include a 22.6% increase in sales of medical products and maintenance services. The company opened 14 new clinics across eight core cities. However, average mobile MAUs decreased to 1.5 million from 3.0 million in Q2 2023. For Q3 2024, So-Young expects total revenues between RMB350.0 million and RMB370.0 million, representing a 9.2% to 4.0% year-over-year decrease.

Positive

• Total revenues of RMB407.4 million (US$56.1 million) exceeded guidance
• Net income of RMB18.9 million (US$2.6 million), compared to a net loss in Q2 2023
• Non-GAAP net income increased to RMB22.2 million (US$3.1 million)
• 22.6% year-over-year increase in sales of medical products and maintenance services
• Opened 14 new clinics across eight core cities
• Beijing clinic leads in key operating metrics, including repeat customer rates and customer acquisition costs

Negative

• Total revenues decreased 1.1% year-over-year
• Average mobile MAUs decreased to 1.5 million from 3.0 million in Q2 2023
• Number of medical service providers subscribing to information services decreased to 1,174 from 1,659 in Q2 2023
• Information services and other revenues decreased 6.6% year-over-year
• Reservation services revenues decreased 16.9% year-over-year
• Q3 2024 revenue guidance suggests a 9.2% to 4.0% year-over-year decrease

News Market Reaction

-4.19%

1 alert

-4.19% News Effect

On the day this news was published, SY declined 4.19%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

BEIJING, Aug. 23, 2024 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced its unaudited financial results for the second quarter ended June 30, 2024.

Second Quarter 2024 Financial Highlights

• Total revenues were RMB407.4 million (US$56.1 million^[1]), compared with RMB412.1 million in the corresponding period of 2023, exceeding the high end of guidance.
• Net income attributable to So-Young International Inc. was RMB18.9 million (US$2.6 million), compared with net loss attributable to So-Young International Inc. of RMB2.6 million in the same period of 2023.
• Non-GAAP net income attributable to So-Young International Inc.^[2] was RMB22.2 million (US$3.1 million), compared with non-GAAP net income attributable to So-Young International Inc. of RMB15.5 million in the same period of 2023.

Second Quarter 2024 Operational Highlights

• Average mobile MAUs were 1.5 million, compared with 3.0 million in the second quarter of 2023.
• Number of medical service providers subscribing to information services on So-Young's platform was 1,174, compared with 1,659 in the second quarter of 2023.
• Total number of purchasing users through reservation services was 137.5 thousand and the aggregate value of medical aesthetic treatment transactions facilitated by So-Young's platform was RMB427.8 million.

Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, commented, "Our performance during the second quarter was solid with total revenue beating guidance on the back of a significant 22.6% year-over-year increase in sales of medical products and maintenance services. This solid performance is directly attributable to our strategic initiatives and ability to capitalize on industry trends and enhance the overall vertical integration and diversification of our business. We made significant progress in expanding our chain of clinics, opening 14 in prime commercial areas across eight core cities. Notably, our Beijing clinic continues to lead the industry in key operating metrics, including repeat customer rates and customer acquisition costs. We plan to swiftly replicate this proven model in other cities to further expand our offline footprint. Leveraging the reputational strength of our brand and extensive consumer behavior data, we have built a solid foundation to drive upstream product development and customization. Product sales continue to grow rapidly with a strong and diversified pipeline currently in development with our partners. Moving forward, we will continue to explore opportunities across the upstream, midstream and downstream sectors, solve industry pain points, and lead the industry towards a new era of quality medical aesthetics."

Mr. Hui Zhao, Chief Financial Officer of So-Young, added, "Growth during the quarter was fueled by the progress we made in integrating our platform across the medical aesthetic value chain. This not only promotes the high-quality and sustainable development of the industry, but also further strengthens our market position. As we accelerate the development of our new businesses, we will continue to prudently manage costs and enhance operational efficiency. We are confident that these strategic initiatives will continue to drive sustainable growth and enhance shareholder value over the long-term."

[1] This press release contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) solely for the convenience of the reader. Unless otherwise specified, all translations of Renminbi amounts into U.S. dollar amounts in this press release are made at RMB7.2672 to US$1.00, which was the U.S. dollars middle rate announced by the Board of Governors of the Federal Reserve System of the United States on June 28, 2024.

[2] Non-GAAP net income/(loss) attributable to So-Young International Inc. is defined as net income/(loss) attributable to So-Young International Inc. excluding share-based compensation expenses attributable to So-Young International Inc. See "Reconciliation of GAAP and Non-GAAP Results" at the end of this press release.

Second Quarter 2024 Financial Results     

Revenues

Total revenues were RMB407.4 million (US$56.1 million), a decrease of 1.1% from RMB412.1 million in the same period of 2023. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young's platform.

• Information services and other revenues were RMB279.2 million (US$38.4 million), a decrease of 6.6% from RMB298.9 million in the same period of 2023. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young's platform.
• Reservation services revenues were RMB22.4 million (US$3.1 million), a decrease of 16.9% from RMB26.9 million in the same period of 2023. The decrease was primarily due to the policy change for commission rates and subsidies.
• Sales of medical products and maintenance services were RMB105.8 million (US$14.6 million), an increase of 22.6% from RMB86.3 million in the same period of 2023, primarily due to an increase in the order volumes for cosmetic products.

Cost of Revenues

Cost of revenues was RMB155.1 million (US$21.3 million), an increase of 3.1% from RMB150.4 million in the second quarter of 2023. The increase was primarily due to an increase in costs associated with sales of cosmetic products. Cost of revenues included share-based compensation expenses of RMB0.2 million (US$0.0 million), compared with the share-based compensation expenses of RMB0.4 million in the corresponding period of 2023.

• Cost of services and others were RMB101.9 million (US$14.0 million), a decrease of 4.4% from RMB106.5 million in the second quarter of 2023. The decrease was primarily due to a decrease in the cost of services associated with So-Young Prime.
• Cost of medical products sold and maintenance services were RMB53.2 million (US$7.3 million), an increase of 21.3% from RMB43.9 million in the second quarter of 2023. The increase was primarily due to an increase in costs associated with the sales of cosmetic products.

Operating Expenses

Total operating expenses were RMB245.6 million (US$33.8 million), a decrease of 13.0% from RMB282.4 million in the second quarter of 2023.

• Sales and marketing expenses were RMB132.3 million (US$18.2 million), a decrease of 4.1% from RMB137.9 million in the second quarter of 2023. The decrease was mainly due to a decrease in expenses associated with branding and user acquisition activities. Sales and marketing expenses included share-based compensation expenses of RMB0.2 million (US$0.0 million), compared with RMB0.8 million in the corresponding period of 2023.
• General and administrative expenses were RMB70.8 million (US$9.7 million), a decrease of 23.3% from RMB92.3 million in the second quarter of 2023. The decrease was primarily due to decreases in share-based compensation expenses and professional consulting fees. General and administrative expenses included share-based compensation expenses of RMB2.0 million (US$0.3 million), compared with RMB15.5 million in the corresponding period of 2023. The decrease in share-based compensation expenses was due to the compensation costs of the restricted share units granted in 2023, which were fully recognized by the end of the first quarter of 2024.
• Research and development expenses were RMB42.5 million (US$5.8 million), a decrease of 18.5% from RMB52.1 million in the second quarter of 2023. The decrease was primarily attributable to improvements in staff efficiency. Research and development expenses included share-based compensation expenses of RMB0.8 million (US$0.1 million), compared with RMB1.3 million in the corresponding period of 2023.

Income Tax Benefits

Income tax benefits were RMB2.6 million (US$0.4 million), compared with income tax benefits of RMB0.8 million in the same period of 2023.

Net Income/(Loss) Attributable to So-Young International Inc.

Net income attributable to So-Young International Inc. was RMB18.9 million (US$2.6 million), compared with a net loss attributable to So-Young International Inc. of RMB2.6 million in the second quarter of 2023.

Non-GAAP Net Income Attributable to So-Young International Inc.

Non-GAAP net income attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses attributable to So-Young International Inc., was RMB22.2 million (US$3.1 million), compared with RMB15.5 million non-GAAP net income attributable to So-Young International Inc. in the same period of 2023.

Basic and Diluted Earnings/(Loss) per ADS

Basic and diluted earnings per ADS attributable to ordinary shareholders were RMB0.18 (US$0.02) and RMB0.18 (US$0.02), respectively, compared with basic and diluted loss per ADS attributable to ordinary shareholders of RMB0.02 and RMB0.02, respectively, in the same period of 2023.

Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments

As of June 30, 2024, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB1,245.1 million (US$171.3 million), compared with RMB1,341.6 million as of December 31, 2023.

Business Outlook

For the third quarter of 2024, So-Young expects total revenues to be between RMB350.0 million (US$48.2 million) and RMB370.0 million (US$50.9 million), representing a 9.2% to 4.0% decrease from the same period in 2023. The above outlook is based on the current market conditions and reflects the Company's preliminary estimates of market and operating conditions, as well as customer demand, which are all subject to change.

Non-GAAP Financial Measures

To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP income/(loss) from operations and non-GAAP net income/(loss) attributable to So-Young International Inc. by excluding share-based compensation expenses from income/(loss) from operations and net income/(loss) attributable to So-Young International Inc., respectively. The Company believes these non-GAAP financial measures are important to help investors understand the Company's operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company's core operating results, as they exclude certain expenses that are not expected to result in cash payments. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses have been and will continue to be incurred in the future. All these are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company's results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company's performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.

Conference Call Information

So-Young's management will hold an earnings conference call on Friday, August 23, 2024, at 7:30 AM U.S. Eastern Time (7:30 PM on the same day, Beijing/Hong Kong Time). Dial-in details for the earnings conference call are as follows:

International:	+1-412-902-4272
Mainland China:	4001-201203
US:	+1-888-346-8982
Hong Kong:	+852-301-84992
Passcode:	So-Young International Inc.

A telephone replay will be available two hours after the conclusion of the conference call through 23:59 U.S. Eastern Time, August 30, 2024. The dial-in details are:

International:	+1-412-317-0088
US:	+1-877-344-7529
Passcode:	3725692

Additionally, a live and archived webcast of this conference call will be available at http://ir.soyoung.com.

About So-Young International Inc.

So-Young International Inc. (Nasdaq: SY) is the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry. The Company presents users with reliable information through offering high quality and trustworthy content together with a multitude of social functions on its platform, as well as by curating medical aesthetic service providers that are carefully selected and vetted. Leveraging So-Young's strong brand image, extensive audience reach, trust from its users, highly engaging social community and data insights, the Company is well-positioned to expand both along the medical aesthetic industry value chain and into the massive, fast-growing consumption healthcare service market.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young's strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young's beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young's strategies; So-Young's future business development, financial condition and results of operations; So-Young's ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young's revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:

So-Young

Investor Relations
Ms. Mona Qiao
Phone: +86-10-8790-2012
E-mail: ir@soyoung.com 

Christensen

In China
Ms. Dee Wang
Phone: +86-10-5900-1548
E-mail: dee.wang@christensencomms.com 

In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: linda.bergkamp@christensencomms.com 

 

SO-YOUNG INTERNATIONAL INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except for share and per share data)
	As of
	December 31,		June 30,		June 30,
	2023		2024		2024
	RMB		RMB		US$
Assets
Current assets:
Cash and cash equivalents	426,119		456,927		62,875
Restricted cash and term deposits	14,695		83,224		11,452
Trade receivables	57,219		81,585		11,226
Inventories	118,924		143,374		19,729
Receivables from online payment platforms	23,158		20,819		2,865
Amounts due from related parties	9,212		10,292		1,416
Term deposits and short-term investments	900,823		704,979		97,008
Prepayment and other current assets	171,774		237,267		32,649
Total current assets	1,721,924		1,738,467		239,220
Non-current assets:
Long-term investments	261,016		278,546		38,329
Intangible assets	145,253		133,104		18,316
Goodwill	540,693		540,693		74,402
Property and equipment, net	116,782		137,162		18,874
Deferred tax assets	78,034		80,626		11,095
Operating lease right-of-use assets	118,408		139,885		19,249
Other non-current assets	232,455		183,546		25,257
Total non-current assets	1,492,641		1,493,562		205,522
Total assets	3,214,565		3,232,029		444,742
Liabilities
Current liabilities:
Short-term borrowings	29,825		39,713		5,465
Taxes payable	56,894		57,567		7,921
Contract liabilities	103,374		95,656		13,163
Salary and welfare payables	86,290		79,716		10,969
Amounts due to related parties	388		138		19
Accrued expenses and other current liabilities	233,913		249,175		34,287
Operating lease liabilities-current	29,739		27,482		3,782
Total current liabilities	540,423		549,447		75,606
Non-current liabilities:
Operating lease liabilities-non current	86,210		114,478		15,753
Deferred tax liabilities	25,082		21,342		2,937
Other non-current liabilities	1,536		1,610		222
Total non-current liabilities	112,828		137,430		18,912
Total liabilities	653,251		686,877		94,518
Shareholders' equity:
Treasury stock	(358,453)		(365,451)		(50,288)
Class A ordinary shares (US$0.0005 par value; 750,000,000      shares authorized as of December 31, 2023 and June 30,      2024; 73,688,044 and 63,422,436 shares issued and      outstanding as of December 31, 2023, 77,387,894 and      66,469,129 shares issued and outstanding as of June 30,      2024, respectively)	238		251		35
Class B ordinary shares (US$ 0.0005 par value; 20,000,000      shares authorized as of December 31, 2023 and June 30,      2024; 12,000,000 shares issued and outstanding as of      December 31, 2023 and June 30, 2024)	37		37		5
Additional paid-in capital	3,080,433		3,065,650		421,847
Statutory reserves	33,855		33,855		4,659
Accumulated deficit	(330,166)		(332,465)		(45,749)
Accumulated other comprehensive income	18,185		23,934		3,293
Total So-Young International Inc. shareholders' equity	2,444,129		2,425,811		333,802
Non-controlling interests	117,185		119,341		16,422
Total shareholders' equity	2,561,314		2,545,152		350,224
Total liabilities and shareholders' equity	3,214,565		3,232,029		444,742

 

 

 

SO-YOUNG INTERNATIONAL INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except for share and per share data)
	For the Three Months Ended						For the Six Months Ended
	June 30, 2023		June 30, 2024		June 30, 2024		June 30, 2023		June 30, 2024		June 30, 2024
	RMB		RMB		US$		RMB		RMB		US$
Revenues:
Information services and others	298,879		279,216		38,421		509,163		487,964		67,146
Reservation services	26,903		22,356		3,076		56,584		45,420		6,250
Sales of medical products and maintenance services	86,284		105,808		14,560		156,422		192,278		26,458
Total revenues	412,066		407,380		56,057		722,169		725,662		99,854
Cost of revenues:
Cost of services and others	(106,519)		(101,853)		(14,015)		(188,019)		(176,075)		(24,229)
Cost of medical products sold and maintenance services	(43,859)		(53,198)		(7,320)		(76,080)		(96,291)		(13,250)
Total cost of revenues	(150,378)		(155,051)		(21,335)		(264,099)		(272,366)		(37,479)
Gross profit	261,688		252,329		34,722		458,070		453,296		62,375
Operating expenses:
Sales and marketing expenses	(137,921)		(132,308)		(18,206)		(250,432)		(245,564)		(33,791)
General and administrative expenses	(92,341)		(70,799)		(9,742)		(153,855)		(155,752)		(21,432)
Research and development expenses	(52,141)		(42,498)		(5,848)		(107,934)		(82,089)		(11,296)
Total operating expenses	(282,403)		(245,605)		(33,796)		(512,221)		(483,405)		(66,519)
(Loss)/Income from operations	(20,715)		6,724		926		(54,151)		(30,109)		(4,144)
Other income/(expenses):
Investment income, net	3,370		788		108		10,222		2,887		397
Interest income, net	13,966		11,718		1,612		25,893		24,031		3,307
Exchange (losses)/gains	(1,579)		16		2		(1,154)		410		56
Share of losses of equity method investee	(3,699)		(3,733)		(514)		(6,870)		(7,729)		(1,064)
Others, net	6,562		2,039		281		8,587		5,319		732
(Loss)/Income before tax	(2,095)		17,552		2,415		(17,473)		(5,191)		(716)
Income tax benefits	785		2,571		354		5,049		5,128		706
Net (loss)/income	(1,310)		20,123		2,769		(12,424)		(63)		(10)
Net income attributable to noncontrolling interests	(1,268)		(1,182)		(163)		(2,102)		(2,236)		(308)
Net (loss)/income attributable to So-Young International Inc.	(2,578)		18,941		2,606		(14,526)		(2,299)		(318)

 

 

SO-YOUNG INTERNATIONAL INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Continued)
(Amounts in thousands, except for share and per share data)
	For the Three Months Ended						For the Six Months Ended
	June 30, 2023		June 30, 2024		June 30, 2024		June 30, 2023		June 30, 2024		June 30, 2024
	RMB		RMB		US$		RMB		RMB		US$
Net (loss)/earnings per ordinary share
Net (loss)/earnings per ordinary share attributable to ordinary shareholder - basic	(0.03)		0.24		0.03		(0.18)		(0.03)		(0.00)
Net (loss)/earnings per ordinary share attributable to ordinary shareholder -      diluted	(0.03)		0.24		0.03		(0.18)		(0.03)		(0.00)
Net (loss)/earnings per ADS attributable to ordinary shareholders - basic (13      ADS represents 10 Class A ordinary shares)	(0.02)		0.18		0.02		(0.14)		(0.02)		(0.00)
Net (loss)/earnings per ADS attributable to ordinary shareholders - diluted (13      ADS represents 10 Class A ordinary shares)	(0.02)		0.18		0.02		(0.14)		(0.02)		(0.00)
Weighted average number of ordinary shares used in computing earnings/(loss)      per share, basic*	77,310,426		79,586,926		79,586,926		78,580,369		79,569,190		79,569,190
Weighted average number of ordinary shares used in computing earnings/(loss)      per share, diluted*	77,310,426		79,899,412		79,899,412		78,580,369		79,569,190		79,569,190
Share-based compensation expenses included in:
Cost of services and others	(412)		(229)		(32)		(1,217)		(174)		(24)
Sales and marketing expenses	(823)		(184)		(25)		(2,317)		(237)		(33)
General and administrative expenses	(15,546)		(2,015)		(277)		(21,564)		(26,468)		(3,642)
Research and development expenses	(1,305)		(817)		(112)		(2,182)		(1,660)		(228)
* Both Class A and Class B ordinary shares are included in the calculation of the weighted average number of ordinary shares outstanding, basic and diluted.

 

 

SO-YOUNG INTERNATIONAL INC.
Reconciliation of GAAP and Non-GAAP Results
(Amounts in thousands, except for share and per share data)
	For the Three Months Ended						For the Six Months Ended
	June 30, 2023		June 30, 2024		June 30, 2024		June 30, 2023		June 30, 2024		June 30, 2024
	RMB		RMB		US$		RMB		RMB		US$
GAAP (loss)/income from operations	(20,715)		6,724		926		(54,151)		(30,109)		(4,144)
Add back: Share-based compensation expenses	18,086		3,245		446		27,280		28,539		3,927
Non-GAAP (loss)/income from operations	(2,629)		9,969		1,372		(26,871)		(1,570)		(217)
GAAP net (loss)/income attributable to So-Young International Inc.	(2,578)		18,941		2,606		(14,526)		(2,299)		(318)
Add back: Share-based compensation expenses	18,086		3,245		446		27,280		28,539		3,927
Non-GAAP net income attributable to So-Young International Inc.	15,508		22,186		3,052		12,754		26,240		3,609

 

 

View original content:https://www.prnewswire.com/news-releases/so-young-reports-unaudited-second-quarter-2024-financial-results-302229399.html

SOURCE So-Young International Inc.

FAQ

What were So-Young's (SY) total revenues in Q2 2024?

So-Young's total revenues in Q2 2024 were RMB407.4 million (US$56.1 million), slightly down 1.1% year-over-year but exceeding the company's guidance.

How did So-Young's (SY) net income change in Q2 2024 compared to Q2 2023?

So-Young reported net income of RMB18.9 million (US$2.6 million) in Q2 2024, compared to a net loss of RMB2.6 million in Q2 2023, showing a significant improvement in profitability.

What was the growth rate of So-Young's (SY) medical products and maintenance services sales in Q2 2024?

So-Young's sales of medical products and maintenance services increased by 22.6% year-over-year in Q2 2024, reaching RMB105.8 million (US$14.6 million).

How many new clinics did So-Young (SY) open in Q2 2024?

So-Young opened 14 new clinics across eight core cities during Q2 2024, expanding its offline footprint.

What is So-Young's (SY) revenue guidance for Q3 2024?

For Q3 2024, So-Young expects total revenues to be between RMB350.0 million (US$48.2 million) and RMB370.0 million (US$50.9 million), representing a 9.2% to 4.0% decrease from the same period in 2023.